Treadwell

Treadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical Officer

Retrieved on: 
Friday, February 3, 2023
Gene editing, Immunotherapy, Royal College of Physicians and Surgeons of Canada, Therapy, Surgeon, University, Royal college, Bachelor, Drug development, Queen, Acquisition, Patient, Drug, Biochemistry, Cross Cancer Institute, Translation, Internal medicine, Research, Oncology, Cell, Amgen, Queen's University, Physician, Treadwell, Oklahoma Office of the Chief Medical Examiner, Roivant Sciences, Pharmaceutical industry, Eterna

NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage, global biotechnology company developing novel, first in class therapeutics for highly aggressive cancers, today announced that it has appointed Roger Sidhu, M.D., as Chief Medical Officer.

Key Points: 
  • NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage, global biotechnology company developing novel, first in class therapeutics for highly aggressive cancers, today announced that it has appointed Roger Sidhu, M.D., as Chief Medical Officer.
  • Dr. Sidhu was most recently the Chief Medical Officer at Brooklyn (now Eterna) ImmunoTherapeutics, a gene editing and cell therapy company where he advanced multiple novel programs.
  • Previously, Dr. Sidhu served as Executive Vice President and Chief Medical officer at Roivant Sciences.
  • Roger was also the Chief Medical Officer at Cell Design Labs, up until its acquisition by the Gilead subsidiary Kite, where he subsequently served as VP, Clinical Development.

Treadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical Officer

Retrieved on: 
Friday, February 3, 2023
Gene editing, Immunotherapy, Royal College of Physicians and Surgeons of Canada, Therapy, Surgeon, University, Royal college, Bachelor, Drug development, Queen, Acquisition, Patient, Drug, Biochemistry, Cross Cancer Institute, Translation, Internal medicine, Research, Oncology, Cell, Amgen, Queen's University, Physician, Treadwell, Oklahoma Office of the Chief Medical Examiner, Roivant Sciences, Pharmaceutical industry, Eterna

NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage, global biotechnology company developing novel, first in class therapeutics for highly aggressive cancers, today announced that it has appointed Roger Sidhu, M.D., as Chief Medical Officer.

Key Points: 
  • NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage, global biotechnology company developing novel, first in class therapeutics for highly aggressive cancers, today announced that it has appointed Roger Sidhu, M.D., as Chief Medical Officer.
  • Dr. Sidhu was most recently the Chief Medical Officer at Brooklyn (now Eterna) ImmunoTherapeutics, a gene editing and cell therapy company where he advanced multiple novel programs.
  • Previously, Dr. Sidhu served as Executive Vice President and Chief Medical officer at Roivant Sciences.
  • Roger was also the Chief Medical Officer at Cell Design Labs, up until its acquisition by the Gilead subsidiary Kite, where he subsequently served as VP, Clinical Development.

Treadwell Therapeutics Announces Fast Track Designation Granted by the FDA to CFI-402257 for the Treatment of ER+/HER2- Breast Cancer

Retrieved on: 
Tuesday, January 10, 2023
Fulvestrant, Patient, Breast cancer, HIV disease progression rates, Treadwell, Food, TTK, Therapy, Fast Track, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry

"There is an urgent need for new, safe and efficacious therapies to treat ER+/HER2- breast cancer, particularly when standard of care regimens fail," said Dr. Mark Bray, Treadwell CSO and Co-founder.

Key Points: 
  • "There is an urgent need for new, safe and efficacious therapies to treat ER+/HER2- breast cancer, particularly when standard of care regimens fail," said Dr. Mark Bray, Treadwell CSO and Co-founder.
  • We are thankful for the Fast Track Designation granted by the FDA and look forward to the continued development of CFI-402257 in ER+/HER2- breast cancer."
  • Fast Track designation seeks to streamline the development and accelerate the review of new agents with potential to treat serious or life-threatening diseases and that potentially address an unmet medical need.
  • Drugs that are granted this designation can have more frequent interactions with the FDA, as well as potential pathways for expedited approval.

Treadwell Therapeutics Announces Fast Track Designation Granted by the FDA to CFI-402257 for the Treatment of ER+/HER2- Breast Cancer

Retrieved on: 
Tuesday, January 10, 2023
Fulvestrant, Patient, Breast cancer, HIV disease progression rates, Treadwell, Food, TTK, Therapy, Fast Track, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry

"There is an urgent need for new, safe and efficacious therapies to treat ER+/HER2- breast cancer, particularly when standard of care regimens fail," said Dr. Mark Bray, Treadwell CSO and Co-founder.

Key Points: 
  • "There is an urgent need for new, safe and efficacious therapies to treat ER+/HER2- breast cancer, particularly when standard of care regimens fail," said Dr. Mark Bray, Treadwell CSO and Co-founder.
  • We are thankful for the Fast Track Designation granted by the FDA and look forward to the continued development of CFI-402257 in ER+/HER2- breast cancer."
  • Fast Track designation seeks to streamline the development and accelerate the review of new agents with potential to treat serious or life-threatening diseases and that potentially address an unmet medical need.
  • Drugs that are granted this designation can have more frequent interactions with the FDA, as well as potential pathways for expedited approval.

Life on the Land TV Show Launches Season 4 on RFD-TV

Retrieved on: 
Tuesday, January 3, 2023
Travel, Windsor, Colorado, Season, CO, Cattle, Treadwell, Collection, RFD-TV, EST, Television, Life, Land

This is the fourth season of taking viewers across the country on tours of amazing properties and interesting lifestyles of rural landowners.

Key Points: 
  • This is the fourth season of taking viewers across the country on tours of amazing properties and interesting lifestyles of rural landowners.
  • This season brings viewers a whole new collection of unique stories that make up the fabric of this country.
  • Life on the Land is sponsored by Hayden Outdoors Real Estate, Outdoor Lending, True Timber Camo, and Western Heritage Consulting & Engineering.
  • The only TV show of its kind, Life on the Land airs on RFD-TV prime time Wednesdays at 8 pm EST.

Treadwell Therapeutics Announces A Presentation at the 2022 ASH Annual Meeting Featuring a Clinical Trial Update on CFI-400945, an oral PLK4 inhibitor

Retrieved on: 
Tuesday, December 13, 2022
Therapy, Poster, IWG, MD, Society, Leukemia, HPK1, Science, TCR, Cancer, Decitabine, MD Anderson Cancer Center, Acute myeloid leukemia, TP53, Treadwell, Multicenter Automatic Defibrillator Implantation Trial, Division, AE, Azacitidine, TTK, Chronic myelomonocytic leukemia, AML, Myelodysplastic syndrome, PLK4, ELN, Toxic leukoencephalopathy, ASH, AES, PD, Febrile neutropenia, Pharmaceutical industry, Tolerability, Safety, Patient

The poster presentation described the preliminary results from the monotherapy dose optimization portion of the TWT-202 in advanced leukemias.

Key Points: 
  • The poster presentation described the preliminary results from the monotherapy dose optimization portion of the TWT-202 in advanced leukemias.
  • "CFI-400945 had previously shown single agent complete remissions in refractory high risk AML.
  • Treadwell Therapeutics is a science driven, clinical-stage, multi-modality biotechnology company developing first-in-class and best-in-class medicines to address unmet needs in patients with cancer.
  • The Company's internally developed clinical pipeline includes CFI-400945, CFI-402257 (TTK inhibitor) and CFI-402411 (HPK1 inhibitor).

Treadwell Therapeutics Announces A Presentation at the 2022 ASH Annual Meeting Featuring a Clinical Trial Update on CFI-400945, an oral PLK4 inhibitor

Retrieved on: 
Tuesday, December 13, 2022
Therapy, Poster, IWG, MD, Society, Leukemia, HPK1, Science, TCR, Cancer, Decitabine, MD Anderson Cancer Center, Acute myeloid leukemia, TP53, Treadwell, Multicenter Automatic Defibrillator Implantation Trial, Division, AE, Azacitidine, TTK, Chronic myelomonocytic leukemia, AML, Myelodysplastic syndrome, PLK4, ELN, Toxic leukoencephalopathy, ASH, AES, PD, Febrile neutropenia, Pharmaceutical industry, Tolerability, Safety, Patient

The poster presentation described the preliminary results from the monotherapy dose optimization portion of the TWT-202 in advanced leukemias.

Key Points: 
  • The poster presentation described the preliminary results from the monotherapy dose optimization portion of the TWT-202 in advanced leukemias.
  • "CFI-400945 had previously shown single agent complete remissions in refractory high risk AML.
  • Treadwell Therapeutics is a science driven, clinical-stage, multi-modality biotechnology company developing first-in-class and best-in-class medicines to address unmet needs in patients with cancer.
  • The Company's internally developed clinical pipeline includes CFI-400945, CFI-402257 (TTK inhibitor) and CFI-402411 (HPK1 inhibitor).

Treadwell Therapeutics Announces Presentations at the 2022 San Antonio Breast Cancer Symposium Featuring a Clinical Trial Update on the CFI-402257 and CFI-400945 programs

Retrieved on: 
Monday, November 21, 2022
2021 Essex County Council election, TTK, Patient, PLK4, Breast cancer, HPK1, Cancer, Therapy, Treadwell, Science, TCR, Pharmaceutical industry

"We are grateful that several abstracts highlighting our TTK and PLK4 inhibitor programs have been selected for presentation," said Dr. Michael Tusche, Treadwell co-CEO.

Key Points: 
  • "We are grateful that several abstracts highlighting our TTK and PLK4 inhibitor programs have been selected for presentation," said Dr. Michael Tusche, Treadwell co-CEO.
  • "We look forward to additional data from these studies, as we further characterize the utility of our agents in various breast cancer settings."
  • The Company's internally developed clinical pipeline includes CFI-400945, CFI-402257 and CFI-402411 (HPK1 inhibitor).
  • The company is also advancing a pre-clinical pipeline of first-in-class antibody and TCR-based cell therapy assets.

Treadwell Therapeutics Announces Presentations at the 2022 San Antonio Breast Cancer Symposium Featuring a Clinical Trial Update on the CFI-402257 and CFI-400945 programs

Retrieved on: 
Monday, November 21, 2022
2021 Essex County Council election, TTK, Patient, PLK4, Breast cancer, HPK1, Cancer, Therapy, Treadwell, Science, TCR, Pharmaceutical industry

"We are grateful that several abstracts highlighting our TTK and PLK4 inhibitor programs have been selected for presentation," said Dr. Michael Tusche, Treadwell co-CEO.

Key Points: 
  • "We are grateful that several abstracts highlighting our TTK and PLK4 inhibitor programs have been selected for presentation," said Dr. Michael Tusche, Treadwell co-CEO.
  • "We look forward to additional data from these studies, as we further characterize the utility of our agents in various breast cancer settings."
  • The Company's internally developed clinical pipeline includes CFI-400945, CFI-402257 and CFI-402411 (HPK1 inhibitor).
  • The company is also advancing a pre-clinical pipeline of first-in-class antibody and TCR-based cell therapy assets.

Discount Tire Launches Pit Pass Concept Store With Mobile-Focused, Drive-Thru Experience

Retrieved on: 
Monday, October 3, 2022
Maintenance, 2019 Monster Energy NASCAR Cup Series, No, Discount Tire, Ford Motor Company, Interstate 985, Treadwell, Tire Rack, Aircraft pilot, Bay, Mustang, NASCAR, Interstate Highway System, Digital, Retail, Heavy equipment, Atlanta

ATLANTA, Oct. 3, 2022 /PRNewswire/ -- Discount Tire announced the Atlanta metro area as the location of its first Pit Pass concept store. The Discount Tire Pit Pass concept is a new retail experience designed to integrate technologies, including embedded tire scanners, digital displays, online ordering, and appointment-focused booking, with speedy tire and wheel services from the comfort of a customer's vehicle in a drive-thru experience. The initial Discount Tire Pit Pass concept store is in Flowery Branch, Georgia, just south of the intersection of Interstate 985 and Highway 53.

Key Points: 
  • The initial Discount Tire Pit Pass concept store is in Flowery Branch, Georgia, just south of the intersection of Interstate 985 and Highway 53.
  • The Discount Tire Pit Pass concept store features an approximate 5,000-square-foot ground floor footprint and 2,600 square feet of subsurface workspace and is markedly different from the traditional tire shop.
  • Customers visiting the Discount Tire Pit Pass concept store are encouraged to shop for tires and wheels online and to book an appointment in advance using the Discount Tire mobile app or DiscountTire.com to save time.
  • Discount Tire's Pit Pass concept store also offers a new experience for customers who need their tire pressure checked.